Hericenones & Erinacines: The Nerve Growth Compounds of Lion’s Mane

Why Lion’s Mane Is Unique Among Medicinal Mushrooms

Most medicinal mushrooms earn their reputation through immune modulation via beta-glucans. Lion’s Mane (Hericium erinaceus) shares that immunological foundation, but it stands apart because it produces two families of low-molecular-weight compounds—hericenones and erinacines—that can cross the blood-brain barrier and directly stimulate the synthesis of nerve growth factor (NGF). No other commonly available mushroom or food source has demonstrated this capability with comparable potency.

NGF is a neurotrophin—a signaling protein critical for the survival, development, and maintenance of neurons, particularly cholinergic neurons in the basal forebrain that are essential for memory and attention. Declining NGF levels are implicated in Alzheimer’s disease, age-related cognitive decline, and peripheral neuropathies. The ability of Lion’s Mane compounds to boost endogenous NGF production rather than supplying exogenous NGF (which cannot cross the blood-brain barrier) represents a fundamentally different and potentially more effective therapeutic strategy.

Chemical Structure and Classification

Both hericenones and erinacines belong to the cyathane diterpenoid family, characterized by a fused 5-6-7 tricyclic ring system. This structural class is relatively rare in nature and appears to be taxonomically restricted to a small number of fungal genera.

Property	Hericenones	Erinacines
Chemical class	Cyathane diterpenoid–fatty acid conjugates	Cyathane diterpenoids (some glycosylated)
Source tissue	Fruiting body	Mycelium (cultured)
Most active member	Hericenone C, D	Erinacine A
Molecular weight	~470–530 Da	~350–450 Da
BBB penetration	Demonstrated (indirect evidence)	Confirmed in animal models
NGF induction potency	Moderate	High (erinacine A: strongest known fungal NGF inducer)
Number identified	8 variants (A–H)	11+ variants (A–K and beyond)

Mechanism of Action

NGF Synthesis Stimulation

The primary mechanism by which hericenones and erinacines exert their neurological effects is through upregulation of NGF gene expression in astrocytes—star-shaped glial cells that support neurons throughout the central nervous system. In cell culture studies, erinacine A has been shown to increase NGF mRNA expression and subsequent protein secretion by 5–7 fold compared to untreated controls.

The signaling pathway appears to involve activation of the JNK (c-Jun N-terminal kinase) pathway, which phosphorylates transcription factors that bind to the NGF gene promoter. This results in increased transcription and translation of NGF protein, which is then secreted by astrocytes and binds to TrkA receptors on nearby neurons, activating survival and growth signaling cascades.

BDNF Enhancement

Beyond NGF, Lion’s Mane compounds also appear to enhance brain-derived neurotrophic factor (BDNF)—another critical neurotrophin involved in synaptic plasticity, learning, and memory. While the mechanism is less well-characterized than NGF induction, animal studies consistently show elevated hippocampal BDNF levels following Lion’s Mane supplementation, suggesting a broader neurotrophic support profile.

Myelin Synthesis

Erinacine A has demonstrated the ability to promote myelination—the formation of the fatty insulating sheath that wraps nerve fibers and enables rapid signal transmission. In animal models of demyelinating disease, erinacine A treatment accelerated remyelination and improved motor function. This mechanism is particularly relevant for peripheral neuropathies and potentially for multiple sclerosis research.

Anti-inflammatory and Antioxidant Activity

Lion’s Mane compounds reduce neuroinflammation through inhibition of NF-kB signaling and suppression of pro-inflammatory cytokines (TNF-alpha, IL-6) in microglial cells. They also demonstrate antioxidant activity by enhancing endogenous antioxidant enzyme expression (SOD, catalase, glutathione peroxidase), protecting neurons from oxidative stress—a major driver of neurodegenerative disease.

Clinical Evidence

Study	Population	Protocol	Key Findings
Mori et al. (2009)	30 adults with mild cognitive impairment, ages 50–80	250 mg tablets 3x/day (96% dry powder) for 16 weeks	Significant improvement on the Revised Hasegawa Dementia Scale at weeks 8, 12, and 16 vs placebo. Cognitive gains reversed 4 weeks after cessation.
Nagano et al. (2010)	30 menopausal women	Four 500 mg cookies daily for 4 weeks	Significantly reduced depression and anxiety scores on the CES-D and IAS scales compared to placebo cookies.
Li et al. (2020)	77 overweight adults with mild cognitive impairment	350 mg erinacine A-enriched mycelium 3x/day for 49 weeks	Improved cognitive scores, reduced brain atrophy on MRI, and increased BDNF blood levels vs placebo.
Saitsu et al. (2019)	31 healthy adults aged 50+	3.2 g/day fruiting body powder for 12 weeks	Improved cognitive function scores; benefits emerged by week 8 and continued through week 12.
Vigna et al. (2019)	77 patients with mild Alzheimer’s	1 g/day for 49 weeks	Slowed cognitive decline with significant improvements in IADL scores and lower biomarkers of neuroinflammation.

A consistent pattern emerges across trials: cognitive benefits require 8–16 weeks of sustained use to manifest, and improvements tend to reverse upon discontinuation. This timeline is consistent with the biological mechanism—NGF-driven neuroplastic remodeling is a slow process requiring sustained neurotrophic support.

Additional Research Areas

• Peripheral neuropathy: Animal studies demonstrate improved nerve conduction velocity and accelerated nerve regeneration following crush injury with erinacine A treatment
• Depression and anxiety: Beyond the Nagano menopausal study, animal models consistently show anxiolytic and antidepressant effects, potentially mediated through hippocampal neurogenesis and BDNF enhancement
• Gastroprotection: Lion’s Mane polysaccharides (distinct from hericenones/erinacines) show protective effects against gastric ulcers and support gut barrier integrity
• Hearing loss: Preliminary animal research suggests erinacines may protect auditory neurons from damage, a novel application area
• Stroke recovery: Animal studies show reduced infarct volume and improved neurological outcomes when erinacine A is administered following ischemic stroke

The Fruiting Body vs. Mycelium Debate

Lion’s Mane presents a unique challenge in the mushroom supplement world because its two primary neuroactive compound families come from different parts of the organism.

Fruiting Body Products

Contain hericenones (A–H) along with beta-glucans, polysaccharides, and other structural compounds. The fruiting body is the visible, cascading white “waterfall” mushroom. Fruiting body extracts are well-characterized and can be standardized to hericenone content. They also provide the immune-modulating beta-glucans found in all medicinal mushrooms.

Mycelium Products

Contain erinacines (A–K), which are generally considered more potent NGF inducers than hericenones. However, most commercial mycelium products are grown on grain substrates, and the final product is a mixture of mycelium and residual grain. This dilutes active compound concentration and introduces alpha-glucans from the grain that have no neurological activity.

The Ideal Approach

For maximum neuroactive potential, the ideal Lion’s Mane supplement would combine a fruiting body extract (standardized for hericenones and beta-glucans) with a purified mycelium extract (standardized for erinacine A content, with grain substrate removed). Some premium products are beginning to offer this dual-extract approach.

Dosing and Administration

Form	Typical Daily Dose	Notes
Dried fruiting body powder	1,000–3,000 mg	Traditional approach; moderate hericenone content
Hot water extract (fruiting body)	500–1,000 mg	Concentrated; standardized products preferred
Dual extract (water + ethanol)	500–1,000 mg	Broader compound profile; captures both polar and non-polar actives
Erinacine A-enriched mycelium	1,050 mg (3 x 350 mg)	Based on Li et al. (2020) clinical protocol
Fresh mushroom (culinary)	100–300 g	Bioactive content variable; primarily dietary benefit

Clinical trials have used treatment periods of 8–49 weeks. The 8-week minimum before cognitive benefits appear is consistently reported, which aligns with the timeline for NGF-driven neuroplastic changes. Continuous use appears necessary to maintain benefits.

Safety Profile

• Excellent tolerability: Lion’s Mane has been consumed as food for centuries in East Asia. Clinical trials report side effect rates comparable to placebo, with mild GI discomfort being the most common complaint
• No known serious adverse effects: No hepatotoxicity, nephrotoxicity, or significant laboratory abnormalities have been reported in clinical trials up to 49 weeks
• Allergy risk: Individuals allergic to mushrooms should avoid Lion’s Mane. Cross-reactivity with other Basidiomycota fungi is possible
• Anticoagulant interaction: Hericenone B has demonstrated in vitro platelet aggregation inhibition. Use caution with anticoagulant or antiplatelet medications
• Immunomodulatory considerations: As with all medicinal mushrooms, theoretical caution applies for autoimmune conditions and immunosuppressive medication users
• Pregnancy and lactation: Insufficient safety data. Traditional use exists but controlled studies are lacking

Connection to Other Nootropics

Lion’s Mane pairs particularly well with other nootropic compounds due to its unique mechanism of action. While racetams and cholinergics enhance neurotransmitter signaling at existing synapses, Lion’s Mane works upstream by promoting the structural growth and survival of the neurons themselves. This makes it complementary to compounds like L-theanine (which modulates neurotransmitter balance), bacopasides from Bacopa (which enhance cholinergic function and dendritic growth), and adaptogenic compounds that reduce neuroinflammatory stress. For a broader perspective on how these compounds interact, see our nootropics overview guide.

References

1. Mori, K. et al. “Improving effects of the mushroom Hericium erinaceus on mild cognitive impairment.” Phytotherapy Research, 2009.
2. Nagano, M. et al. “Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake.” Biomedical Research, 2010.
3. Li, I.C. et al. “Prevention of early Alzheimer’s disease by erinacine A-enriched Hericium erinaceus mycelia.” Frontiers in Aging Neuroscience, 2020.
4. Saitsu, Y. et al. “Improvement of cognitive functions by oral intake of Hericium erinaceus.” Biomedical Research, 2019.
5. Lai, P.L. et al. “Neurotrophic properties of the Lion’s Mane medicinal mushroom.” International Journal of Medicinal Mushrooms, 2013.
6. Chong, P.S. et al. “Therapeutic potential of Hericium erinaceus for depressive disorder.” International Journal of Molecular Sciences, 2020.
7. Martínez-Mármol, R. et al. “Hericene A activates neurotrophin signaling to promote neurite outgrowth.” Journal of Neurochemistry, 2023.